2'-富科西拉克托斯抑制了人类肠道内中人类诺罗病毒的复制
Ketki Patil1, B Vijayalakshmi Ayyar1, Frederick H Neill1
1Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
bioRxiv : the preprint server for biology
|June 10, 2024
概括
2'-富可酸乳糖 (2'FL) 显示出作为人类诺罗病毒 (HuNoV) 胃肠炎的抗病毒疗法的潜力. 这种化合物显著减少了肠道模型中的HuNoV复制,这表明了新的治疗途径.
科学领域:
- 病毒学 病毒学
- 胃肠病学 胃肠病学
- 葡萄糖生物学 葡萄糖生物学
背景情况:
- 人类诺病毒 (HuNoVs) 是全球急性胃肠炎的主要原因.
- 目前没有针对HuNoV感染的特定抗病毒治疗方法.
- 基因组血型抗原 (HBGAs) 是HuNoVs的关键附着因子,是抗病毒开发的目标.
研究的目的:
- 为了评估2'-fucosyllactose (2'FL) 的有效性,一个人乳寡糖化物 (HMO),在抑制流行GII.4悉尼[P16]HuNoV菌株的复制.
- 评估2'FL作为治疗HuNoV胃肠炎的治疗剂的潜力.
主要方法:
- 使用了来自成人和儿科捐赠者的人类肠道肠 (HIEs).
- 在这些HIE模型中评估了2'FL对GII.4悉尼[P16]HuNoV复制的影响.
- 与HIEs中特定的fucosylated glycans的表达水平相关的抑制.
主要成果:
- 显著减少GII.4悉尼[P16] HuNoV复制观察到成年十二指肠和结肠HIEs,以及成年器官捐献者的小肠段.
- 2'FL还抑制了儿科十二指肠HIEs中的病毒复制.
- 在婴儿内性HIEs中没有观察到抑制,α1-2-fucosylated glycans的表达较低.
结论:
- 2'-富可酸乳糖 (2'FL) 显示出作为治疗人类诺罗病毒 (HuNoV) 胃肠炎的治疗剂的显著潜力.
- 2'FL的有效性与表达特定的fucosylated glycans有关,它们充当诱受体.
- 可扩展的合成和已确定的安全概况支持进一步开发2'FL用于临床使用.
相关概念视频
Viral Recombination
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
Viruses with RNA Genomes
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...


